{
    "clinical_study": {
        "@rank": "156494", 
        "acronym": "CIRCLES", 
        "arm_group": [
            {
                "arm_group_label": "Full dose blueberry", 
                "arm_group_type": "Active Comparator", 
                "description": "26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.\nFrequency: 26g per day.\nTotal duration: 6-month."
            }, 
            {
                "arm_group_label": "Half dose blueberry", 
                "arm_group_type": "Active Comparator", 
                "description": "26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.\nFrequency: 26g per day.\nTotal duration: 6-month."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched control powder; matched for appearance, taste and sugar content.\nFrequency: 26g per day.\nTotal duration: 6-month."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the dose-dependent impact of 6 month freeze-dried\n      blueberry powder intake on insulin sensitivity and resistance, cardiovascular disease risk\n      factors, and lung and cognitive function in overweight and obese participants with metabolic\n      syndrome. We will also examine acute post-prandial effects of blueberry intake (at baseline\n      and at 6-months)."
        }, 
        "brief_title": "The Health Effects of Blueberry Anthocyanins in Metabolic Syndrome (the CIRCLES-study)", 
        "completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Insulin Resistance", 
            "Metabolic Syndrome X"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Insulin Resistance", 
                "Metabolic Syndrome X"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and postmenopausal women (\u2265 1 year since last menstruation)\n\n          -  50 to 75 years old\n\n          -  BMI of \u2265 25 kg/m2 to \u2264 40 kg/m2\n\n          -  3 characteristics of metabolic syndrome i.e: Waist circumference \u2265 102 cm for men, \u2265\n             88 cm for women; Triglycerides \u2265 1.7 mmol/L (or drug treatment for elevated\n             triglycerides); HDL-cholesterol < 1.0 mmol/L for men, < 1.3 mmol/L for women (or drug\n             treatment for low HDL-cholesterol); Blood pressure \u2265 130 mm Hg systolic and/or \u2265 85\n             mm Hg diastolic blood pressure; Fasting blood glucose \u2265 5.56 mmol/L\n\n          -  Successful biochemical, haematological and urinalysis assessment at screening\n\n        Exclusion Criteria:\n\n          -  Current smokers, or ex-smokers ceasing < 6 months ago\n\n          -  Existing or significant past medical history of vascular disease or medical\n             conditions likely to affect the study measures\n\n          -  Fructose intolerance or known allergies to the intervention treatments\n\n          -  On therapeutic diets or having experienced substantial weight loss within 3 months of\n             screening\n\n          -  Taking flavonoid containing supplements (and unwilling to cease intake during, and 1\n             month preceding the trial)\n\n          -  Planning on altering consumption of vitamin supplements / fish oil capsules during\n             the course of the study.\n\n          -  Prescribed anti-hypertension, hypoglycaemic, vasodilators or HRT medication.\n\n          -  Unsatisfactory biochemical, haematological or urinary assessment at screening, or\n             measures considered to be counter indicative for the study\n\n          -  < 3 characteristics of the metabolic syndrome."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02035592", 
            "org_study_id": "R21478-C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Full dose blueberry", 
                "description": "Full dose: 26g of freeze dried blueberry powder  to be incorporated into the habitual diet.\nDietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.", 
                "intervention_name": "Full dose blueberry", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Half dose blueberry", 
                "description": "Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.\nDietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.", 
                "intervention_name": "Half dose blueberry", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Control: 26g of placebo comparator material to be incorporated into the habitual diet.\nDietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.", 
                "intervention_name": "Control", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Harvard School of Public Health"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "state": "Cambridgeshire", 
                        "zip": "CB2 0QQ"
                    }, 
                    "name": "Addenbrooke's hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "P.Curtis@uea.ac.uk", 
                    "last_name": "Peter J Curtis, PhD", 
                    "phone": "+441603591873"
                }, 
                "contact_backup": {
                    "email": "L.Berends@uea.ac.uk", 
                    "last_name": "Lindsey M Berends, PhD", 
                    "phone": "+44 (0)1603 597162"
                }, 
                "facility": {
                    "address": {
                        "city": "Norwich", 
                        "country": "United Kingdom", 
                        "state": "Norfolk", 
                        "zip": "NR4 7TJ"
                    }, 
                    "name": "Norwich Medical School University of East Anglia"
                }, 
                "investigator": [
                    {
                        "last_name": "Aedin Cassidy, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "John F Potter, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Anne-Marie Minihane, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Colin Kay, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andrew Wilson, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Peter J Curtis, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Luisa M Ostertag, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Lindsey M Berends, PhD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Glyn Johnson, PhD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwich", 
                        "country": "United Kingdom", 
                        "state": "Norfolk", 
                        "zip": "NR4 7UY"
                    }, 
                    "name": "Norfolk and Norwich University Hospital"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "The Effects of Blueberry Anthocyanins on Insulin Resistance and Vascular, Lung and Cognitive Function in a Population With Metabolic Syndrome.", 
        "overall_contact": {
            "email": "P.Curtis@uea.ac.uk", 
            "last_name": "Peter J Curtis, PhD", 
            "phone": "+441603591873"
        }, 
        "overall_contact_backup": {
            "email": "L.Berends@uea.ac.uk", 
            "last_name": "Lindsey M Berends, PhD", 
            "phone": "+441603597162"
        }, 
        "overall_official": {
            "affiliation": "University of East Anglia", 
            "last_name": "Aedin Cassidy, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessed, in the fasted state, via HOMA-IR calculation in all participants; indirect assessment.", 
            "measure": "Insulin resistance", 
            "safety_issue": "No", 
            "time_frame": "Chronic (0 to 6 month)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02035592"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessed in a sub-group via hyperinsulinemic euglycaemic clamp.", 
                "measure": "Insulin resistance", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "Measurements taken of arterial stiffness, endothelial function and blood pressure.", 
                "measure": "Blood pressure and blood vessel regulation", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "Assessed via standard spirometry techniques and biological assessment of exhaled samples.", 
                "measure": "Lung function", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "Assessed via a validated cognitive test battery.", 
                "measure": "Cognitive function", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "Assessment via 3T MRI in a sub-group of participants.", 
                "measure": "Liver fat and blood flow assessment", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "Flavonoid and metabolite levels will be assessed in blood and 24 hour urine samples.", 
                "measure": "Bio-availability", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "The gut microbiome will be assessed from faecal sample collection and the impact on metabolism and of genotype, will be assessed via a targeted approach.", 
                "measure": "Metabolite phenotype effects", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }, 
            {
                "description": "Insulin resistance, lipaemia, vascular, cognitive and lung function measured pre- and post-intervention in combination with a high fat challenge in a sub-group of participants. Urine samples and blood samples (over a 24 hour period) will be taken for biomarker analysis.", 
                "measure": "Acute +24 hour effect of single (26g) intervention intake, given with high fat challenge", 
                "safety_issue": "No", 
                "time_frame": "Chronic (0 to 6 month)"
            }
        ], 
        "source": "University of East Anglia", 
        "sponsors": {
            "collaborator": {
                "agency": "Harvard School of Public Health", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of East Anglia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}